carboxyamido-triazole has been researched along with batimastat in 2 studies
| Studies (carboxyamido-triazole) | Trials (carboxyamido-triazole) | Recent Studies (post-2010) (carboxyamido-triazole) | Studies (batimastat) | Trials (batimastat) | Recent Studies (post-2010) (batimastat) |
|---|---|---|---|---|---|
| 105 | 15 | 22 | 347 | 6 | 56 |
| Protein | Taxonomy | carboxyamido-triazole (IC50) | batimastat (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 3E | Homo sapiens (human) | 0.025 | |
| 5-hydroxytryptamine receptor 3B | Homo sapiens (human) | 0.025 | |
| Interstitial collagenase | Homo sapiens (human) | 0.3158 | |
| Low affinity immunoglobulin epsilon Fc receptor | Homo sapiens (human) | 0.1 | |
| 72 kDa type IV collagenase | Homo sapiens (human) | 0.3029 | |
| Stromelysin-1 | Homo sapiens (human) | 1.1205 | |
| Matrilysin | Homo sapiens (human) | 3.5012 | |
| Matrix metalloproteinase-9 | Homo sapiens (human) | 0.0066 | |
| Neutrophil collagenase | Homo sapiens (human) | 0.7 | |
| Metabotropic glutamate receptor 5 | Rattus norvegicus (Norway rat) | 1.2 | |
| Collagenase 3 | Homo sapiens (human) | 0.005 | |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | 0.025 | |
| Matrix metalloproteinase-14 | Homo sapiens (human) | 0.5715 | |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | 0.0149 | |
| Snake venom metalloproteinase BaP1 | Bothrops asper (terciopelo) | 1.2 | |
| 5-hydroxytryptamine receptor 3D | Homo sapiens (human) | 0.025 | |
| 5-hydroxytryptamine receptor 3C | Homo sapiens (human) | 0.025 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kuwano, M; Ono, M | 1 |
| Bu, W; Li, XM; Qin, LX; Tang, ZY; Xia, JL | 1 |
1 review(s) available for carboxyamido-triazole and batimastat
| Article | Year |
|---|---|
[Development of anti tumor agents targeting angiogenesis].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclohexanes; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Hydroxamic Acids; Interferon-alpha; Interleukin-12; Neoplasms; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Phenylalanine; Platelet Factor 4; Polysaccharides, Bacterial; Sesquiterpenes; Thalidomide; Thiophenes; Triazines; Triazoles; Tumor Cells, Cultured | 1997 |
1 other study(ies) available for carboxyamido-triazole and batimastat
| Article | Year |
|---|---|
Effect of antiangiogenic agents on experimental animal models of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Division; Cyclohexanes; Liver Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Phenylalanine; Sesquiterpenes; Suramin; Thiophenes; Triazoles | 1999 |